Tissue-agnostic RET inhibition: can you trust your target?

Angelica D'Aiello; Balazs Halmos

doi:10.1016/S1470-2045(22)00556-3

Tissue-agnostic RET inhibition: can you trust your target?

Angelica D'Aiello, Balazs Halmos

Oncology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1235-1237
Number of pages	3
Journal	The Lancet Oncology
Volume	23
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(22)00556-3
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(22)00556-3

Cite this

@article{0094d028475041b1ad27aacc3a22d64a,

title = "Tissue-agnostic RET inhibition: can you trust your target?",

author = "Angelica D'Aiello and Balazs Halmos",

note = "Funding Information: BH reports research funding from Boehringer Ingelheim, AstraZeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GlaxoSmithKline, Beigene, and Janssen (to BH's institution), and consulting fees from AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus, and Veracyte (to BH). AD{\textquoteright}A declares no competing interests.",

year = "2022",

month = oct,

doi = "10.1016/S1470-2045(22)00556-3",

language = "English (US)",

volume = "23",

pages = "1235--1237",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Tissue-agnostic RET inhibition

T2 - can you trust your target?

AU - D'Aiello, Angelica

AU - Halmos, Balazs

N1 - Funding Information: BH reports research funding from Boehringer Ingelheim, AstraZeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GlaxoSmithKline, Beigene, and Janssen (to BH's institution), and consulting fees from AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus, and Veracyte (to BH). AD’A declares no competing interests.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85138771687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138771687&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00556-3

DO - 10.1016/S1470-2045(22)00556-3

M3 - Comment/debate

C2 - 36108663

AN - SCOPUS:85138771687

SN - 1470-2045

VL - 23

SP - 1235

EP - 1237

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 10

ER -

Tissue-agnostic RET inhibition: can you trust your target?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this